PMID- 36143844
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20220930
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 9
DP  - 2022 Aug 27
TI  - Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in 
      Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A 
      Prospective, Observational Study.
LID - 10.3390/medicina58091167 [doi]
LID - 1167
AB  - Background and Objectives: Individuals with type 2 diabetes mellitus (T2DM) have 
      an increased risk of cardiovascular disease. Arterial stiffness is an independent 
      prognostic marker for cardiovascular disease development. We aimed at determining 
      the effect of two different sodium-glucose co-transporter-2 (SGLT-2) inhibitors 
      on ambulatory arterial stiffness in individuals with T2DM. Materials and Methods: 
      In this single-center, single-arm, prospective study performed from January 2020 
      to August 2021, we planned to enroll adult subjects with T2DM and stable 
      antidiabetic and antihypertensive treatment, assigned either to empagliflozin or 
      dapagliflozin for 6 months. All eligible subjects underwent ambulatory blood 
      pressure monitoring. We set as the primary efficacy outcome the change in 
      ambulatory pulse wave velocity (PWV) from baseline to week 24. Results: We 
      finally enrolled 46 diabetic subjects, with a mean age of 62.89 (8.53) years and 
      mean T2DM duration of 9.72 (6.37) years. Thirty patients received dapagliflozin, 
      while sixteen patients received empagliflozin. Due to COVID-19 pandemic 
      restrictive measures during the study, the mean follow-up period extended from 6 
      months to 9.98 (3.27) months. Regarding the prespecified primary efficacy 
      outcome, we found that the SGLT-2 inhibitor treatment did not have a significant 
      effect on PWV (p = 0.65). Prior history of cardiovascular disease did not 
      significantly affect the observed effects. Other indices of arterial stiffness, 
      such as augmentation index and central pulse pressure, were not significantly 
      affected, neither by empagliflozin nor by dapagliflozin. Conclusions: SGLT-2 
      inhibitor treatment with empagliflozin or dapagliflozin in subjects with T2DM 
      failed to improve ambulatory PWV over a mean follow-up of 10 months. Registration 
      number: ISRCTN88851713.
FAU - Patoulias, Dimitrios
AU  - Patoulias D
AD  - Second Propaedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
FAU - Papadopoulos, Christodoulos
AU  - Papadopoulos C
AUID- ORCID: 0000-0001-9643-9066
AD  - Third Department of Cardiology, General Hospital "Hippokration", Aristotle 
      University of Thessaloniki, 54124 Thessaloniki, Greece.
FAU - Zografou, Ioanna
AU  - Zografou I
AD  - Second Propaedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
FAU - Katsimardou, Alexandra
AU  - Katsimardou A
AD  - Second Propaedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
FAU - Karagiannis, Asterios
AU  - Karagiannis A
AD  - Second Propaedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
FAU - Doumas, Michael
AU  - Doumas M
AD  - Second Propaedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220827
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Symporters)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 9NEZ333N27 (Sodium)
RN  - HDC1R2M35U (empagliflozin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Antihypertensive Agents/pharmacology
MH  - Benzhydryl Compounds
MH  - Blood Pressure Monitoring, Ambulatory
MH  - *COVID-19
MH  - *Cardiovascular Diseases/chemically induced
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucose
MH  - Glucosides
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Middle Aged
MH  - Morbidity
MH  - Pandemics
MH  - Prospective Studies
MH  - Pulse Wave Analysis
MH  - Sodium
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Symporters/pharmacology
MH  - Treatment Outcome
MH  - *Vascular Stiffness
PMC - PMC9501055
OTO - NOTNLM
OT  - SGLT-2 inhibitor
OT  - arterial stiffness
OT  - cardiovascular disease
OT  - dapagliflozin
OT  - empagliflozin
OT  - pulse wave velocity
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/28 06:00
PMCR- 2022/08/27
CRDT- 2022/09/23 01:32
PHST- 2022/07/19 00:00 [received]
PHST- 2022/08/18 00:00 [revised]
PHST- 2022/08/26 00:00 [accepted]
PHST- 2022/09/23 01:32 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/08/27 00:00 [pmc-release]
AID - medicina58091167 [pii]
AID - medicina-58-01167 [pii]
AID - 10.3390/medicina58091167 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Aug 27;58(9):1167. doi: 10.3390/medicina58091167.